CHU Rennes, Pôle Anesthésie et Réanimation, Inserm, NuMeCan, CIC 1414 and Université de Rennes 1, Rennes, France.
Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'investigation clinique de Rennes, service de pharmacologie clinique), Rennes, France.
BMJ Open. 2018 Jun 30;8(6):e020873. doi: 10.1136/bmjopen-2017-020873.
Reducing opioid consumption during and after surgery has been recommended for more than 10 years. Opioid-free anaesthesia (OFA) is a multimodal anaesthesia associating hypnotics, NMDA antagonists, local anaesthetics, anti-inflammatory drugs and α-2 agonists. Proofs of the effect of OFA on reducing opioid-related adverse effects after major or intermediate non-cardiac surgery are still scarce. We hypothesised that the reduced opioid consumption allowed by OFA compared with standard of care will be associated with a reduction of postoperative opioid-related adverse events.
METHODS/ANALYSIS: The POFA trial is a prospective, randomised, parallel, single-blind, multicentre study of 400 patients undergoing elective intermediate or major non-cardiac surgery. Patients will be randomly allocated to receive either a standard anaesthesia protocol or an OFA. The primary outcome measure is the occurrence of a severe postoperative opioid-related adverse event within the first 48 hours after extubation defined as: postoperative hypoxaemia or postoperative ileus or postoperative cognitive dysfunction. In addition, each component of the primary outcome measure will be analysed separately. Data will be analysed on the intention-to-treat principle and a per-protocol basis.
The POFA trial has been approved by an independent ethics committee for all study centres. Participant recruitment begins in November 2017. Results will be published in international peer-reviewed medical journals.
NCT03316339; Pre-results.
减少手术期间和手术后的阿片类药物消耗已被推荐超过 10 年。无阿片类麻醉(OFA)是一种联合使用催眠药、NMDA 拮抗剂、局部麻醉剂、抗炎药和α-2 激动剂的多模式麻醉。OFA 减少主要或中等非心脏手术后阿片类药物相关不良反应的效果的证据仍然很少。我们假设与标准护理相比,OFA 允许减少阿片类药物的消耗将与减少术后阿片类药物相关不良事件相关。
方法/分析:POFA 试验是一项前瞻性、随机、平行、单盲、多中心研究,涉及 400 例接受择期中等或主要非心脏手术的患者。患者将被随机分配接受标准麻醉方案或 OFA。主要结局测量是拔管后 48 小时内发生严重的术后阿片类药物相关不良事件,定义为:术后低氧血症、术后肠梗阻或术后认知功能障碍。此外,还将分别分析主要结局测量的每个组成部分。数据将根据意向治疗原则和方案进行分析。
POFA 试验已获得所有研究中心的独立伦理委员会的批准。参与者招募于 2017 年 11 月开始。结果将发表在国际同行评议的医学期刊上。
NCT03316339;预结果。